Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities
Net loss	$ (119,891)	$ (99,720)
Adjustments to reconcile net loss to net cash used in operating activities
Non-cash interest expense	4,672	6,131
Non-cash loss on extinguishment of convertible notes due 2020	14,566
Loss on disposal of property and equipment	227
Gain on sale of property and equipment	(40)
Depreciation and amortization expense	5,210	4,320
Stock-based compensation expense	11,061	12,027
Changes in operating assets and liabilities:
Accounts receivable	(15,687)	1,262
Inventory	(10,745)
Accounts payable, accrued expenses and other	(2,367)	335
Deferred revenues	(28,396)	(25,922)
Other assets and liabilities, net	2,046	(481)
Net cash used in operating activities	(139,344)	(102,048)
Cash flows from investing activities
Purchases of marketable securities	(84,262)
Proceeds from sales and maturities of marketable securities	72,160	81,899
Purchases of property and equipment	(2,868)	(8,127)
Net cash (used in) provided by investing activities	(14,970)	73,772
Cash flows from financing activities
Proceeds from exercise of options and warrants to purchase common stock	4,007	8,295
Proceeds from issuance of convertible promissory notes by Silver Creek Pharmaceuticals, Inc.	1,185
Proceeds from at the market offering, net of issuance costs		38,560
Proceeds from issuance of preferred stock by Silver Creek Pharmaceuticals, Inc.		2,083
Other financing activities, net	(21)
Net cash provided by financing activities	5,171	48,938
Net (decrease) increase in cash and cash equivalents	(149,143)	20,662
Cash and cash equivalents, beginning of period	185,606	35,688
Cash and cash equivalents, end of period	36,463	56,350
Non-cash investing and financing activities
Purchases of property and equipment in accounts payable, accrued expenses and other	105	1,800
Receivables related to stock option exercises in prepaid expenses and other current assets	39	87
Receivables related to the sale of property and equipment in prepaid expenses and other current assets	40
Principal amount of convertible notes due 2020 converted into shares of common stock	64,209
Transaction costs related to conversion of convertible notes due 2020 in accounts payable, accrued expenses and other	148
Supplemental disclosure of cash flows
Cash paid for interest	$ 13,851	$ 8,837